Related Experiment Video
Updated: Mar 21, 2026

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
Published on: July 24, 2021
Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort
Kimberly G Blumenthal1, James L Kuhlen2, Ana A Weil3
1Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Department of Medicine, Harvard Medical School, Boston, Mass; Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Mass.
Background:
Ceftaroline fosamil is a cephalosporin approved for treating skin and soft tissue infections (SSTIs), including those caused by methicillin-resistant Staphylococcus aureus and community-acquired pneumonia (CAP).
Objectives:
We aimed to study ceftaroline use and associated adverse drug reactions (ADRs), including hypersensitivity reactions (HSRs), among inpatients.
Methods:
We performed a retrospective electronic health record review of inpatients from Massachusetts General Hospital and Brigham and Women's Hospital who received ceftaroline between May 2012 and February 2015. ADRs diagnosed by clinical providers during the course of clinical care were subsequently verified and classified. Risk factors for ADRs were identified.
Results:
Among 96 patients (median age, 57 years; 54% females) who received a median of 28 (interquartile range, 6-63) ceftaroline doses, 54% were being treated for methicillin-resistant Staphylococcus aureus and treatment indications other than SSTI and CAP comprised 59% of care. There were 31 ADRs observed in 20 (21%) patients; hematologic (n = 15) and cutaneous (n = 9) findings were most common. Observed HSRs included rash with mucosal lesions (n = 1), rash with skin desquamation (n = 1), and possible organ-specific HSRs (n = 2). Patients who suffered an ADR received more doses of ceftaroline (median, 46 vs 21; P = .013). There was no increased risk of ceftaroline ADR among patients with reported beta-lactam allergy history (P > .5).
Conclusions:
Ceftaroline is used to treat a range of infections beyond SSTI and CAP. We observed a high rate of ADRs from ceftaroline, including signs of severe HSRs. More data are needed to understand the frequency and predictors of ceftaroline ADRs and HSRs.
Insights
Ceftaroline is used for infections beyond skin and pneumonia. This study found a high rate of adverse drug reactions (ADRs), including severe hypersensitivity reactions (HSRs), indicating a need for further research.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Pharmacy
Background:
- Ceftaroline fosamil is a cephalosporin antibiotic approved for treating skin and soft tissue infections (SSTIs) and community-acquired pneumonia (CAP).
- Its use extends to infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
Observation:
- A retrospective review of 96 inpatients receiving ceftaroline between May 2012 and February 2015 was conducted.
- The study analyzed diagnosed adverse drug reactions (ADRs), including hypersensitivity reactions (HSRs).
- Risk factors for ADRs were identified.
Findings:
- Ceftaroline was administered for various infections, with 54% of patients treated for MRSA.
- 21% of patients experienced ADRs, most commonly hematologic (15) and cutaneous (9) findings.
- Severe HSRs were observed, and patients with ADRs received more ceftaroline doses (median 46 vs 21).
- No increased risk of ADRs was associated with a history of beta-lactam allergy.
Implications:
- Ceftaroline's clinical utility extends beyond its approved indications.
- A significant rate of ADRs, including severe HSRs, was observed.
- Further research is necessary to elucidate the frequency and predictors of ceftaroline-associated ADRs and HSRs.
Related Concept Videos
Inhibitors of Bacterial DNA Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Mechanism of Antibiotic Resistance in MRSA
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Hypersensitivity Reactions: Cytolytic Reactions
Drug Toxicity: Allergic Reactions

